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Keeping in mind the pharmacological importance of the 1,3,4-oxadiazole moiety, a series of new 
S-substituted derivatives, 5a-h, of 5-(1-(4-tosyl)piperidin-4-yl)-1,3,4-oxadiazol-2-thiol (3) were 
synthesized. The reaction of p-toluenesulfonyl chloride (a) and ethyl isonipecotate (b) produced 
ethyl 1-(4-tosyl)piperidin-4-carboxylate (1) which was further transformed into 1-(4-tosyl)piperidin-
4-carbohydrazide (2) by hydrazine hydrate in methanol. Compound 2 was refluxed with CS2 in the 
presence of KOH to synthesize 5-(1-(4-tosyl)piperidin-4-yl)-1,3,4-oxadiazol-2-thiol (3). The desired 
compounds, 5a-h, were synthesized by stirring 3 with aralkyl halides, 4a-h, in DMF using NaH as an 
activator. The structures of synthesized compounds were elucidated by 1H-NMR, IR and EI-MS spectral 
studies. These compounds were further evaluated for enzyme inhibitory activity against lipoxygenase and 
alpha-glucosidase, along with antibacterial activity against Gram-negative and Gram-positive bacteria.
Uniterms: 1,3,4-Oxadiazole/antibacterial activity. 1,3,4-Oxadiazole/enzyme inhibitory activity. 
Isonipecotate.  Sulfonamide.
Tendo em vista a importância farmacológica da porção 1,3,4-oxadiazol, sintetizou-se uma série de 
novos derivados S-substituídos, 5a-h, de 5-(1-(4-tosi)piperidin-4-il)-1,3,4-oxadiazol-2-tiol (3). A reação 
do cloreto de p-toluenossulfonila (a), com isonipecotato de (b) etila forneceu 1-(4-tosil)piperidin-4-
carboxilato de metila (1), que foi, em seguida, transformado em 1-(4-tosil)piperidin-4-carbo-hidrazida 
(2) por reação com hidrato de hidrazina em metanol. O composto 2 foi submetido a refluxo com CS2 na 
presença de KOH para se obter 5-(1-(4-tosil)piperidin-4-il)-1,3,4-oxadiazol-2-tiol (3). Os compostos 
desejados, 5a-h, foram obtidos por agitação de 3 com haletos de aralquila, 4a-h, em DMF, na presença 
de NaH. As estruturas dos compostos sintetizados foram elucidadas através de análise dos espectros 
de 1H-MNR, IR e EI-MS. Estes compostos foram, ainda, avaliados quanto à inibição das enzimas 
lipoxigenase e alfa-glucosidase, juntamente com a atividade antibacteriana contra bactérias Gram 
positivas e Gram negativas.
Unitermos: 1,3,4-Oxadiazol/atividade antibacteriana. 1,3,4-Oxadiazol/inibição enzimática. Isonipecotato. 
Sulfonamida.
INTRODUCTION
Scientists have been working to develop new 
drugs for combating and controlling different diseases 
for decades. This task has been taken up by chemists and 
pharmacologists to design and synthesize novel drugs to 
treat various disorders and diseases in plants, animals and 
especially humans, resulting in the emergence of various 
drugs. Sulfonamide, oxadiazole and piperidine derivatives 
with significant pharmacological activities have been 
introduced.
1,3,4-Oxadiazoles comprise a class of heterocyclic 
compounds that have a wide variety of biological 
activities. Their derivatives show, for example, remarkable 
antiproliferative (El-Din et al., 2015), antihepatitis (Tan 
et al., 2006), antitumor (Zhang et al., 2014), anticancer 
(Kumar et al., 2009), antiinflammatory (Omar et al., 
1996), and antibacterial (Bhardwaj et al., 2009; Li et al., 
A. Sattar, Aziz-ur-Rehman, M. A. Abbasi, S. Z. Siddiqui, S. Rasool, I. Ahmad78
2014; Shafi, Radhakrishnan, 1995) activities. Piperidine-
bearing compounds are well known for their therapeutic 
potential. A number of these compounds have been 
synthesized and evaluated for pharmacological potential 
(Sanchez-Sancho, Herrandón, 1998). These compounds 
are used to control plasma insulin and glucose levels, in 
cocaine abuse treatment and also as anesthetics (Nithiya et 
al., 2011). Sulfonamides are also potent pharmacological 
and therapeutic agents which are used as antibacterial 
agents and inhibitors of different disease-related enzymes. 
These compounds are also used as anticancer drugs, 
diuretics and hypoglycemic agents (Adger et al., 1996; 
Aziz-ur-Rehman et al., 2011).
As an extension of the last work by our group 
(Aziz-ur-Rehman et al., 2014; Nafeesa et al., 2015), 
the very attractive biological activities of the above-
mentioned classes of compounds prompted us to 
synthesize compounds bearing three moieties, namely 
1,3,4-oxadiazole, piperidine and sulfonamide. These new 
compounds were evaluated for their pharmacological 
potential as antibacterial and anti-enzymatic agents.
MATERIAL AND METHODS
General
The melting points of synthesized compounds 
were determined with a Griffin and George melting 
point apparatus using an open capillary tube and were 
uncorrected. The purity of the synthesized compounds 
was confirmed using thin-layer chromatography (TLC), 
performed on aluminum plates pre-coated with silica gel 
G-25-UV254, carried out under different solvent systems 
with varying ratios of ethyl acetate and n-hexane to obtain 
a single spot, visualized using a 254-nm UV lamp. The 
IR spectra were recorded using the KBr pellet method 
on a Jasco-320-A spectrometer (wave number in cm-1). 
Proton nuclear magnetic resonance spectra were recorded 
in CDCl3 solvent on a Bruker spectrometer operating at 
400 MHz. Chemical shifts are given in ppm. Mass spectra 
(EIMS) were recorded on a JMS-HX-110 spectrometer, 
with a data system.
Preparation of ethyl 1-(4-tosyl)piperidin-4-
carboxylate (1)
Ethyl isonipecotate (b; 15.0 mmol) was dissolved in 
15 mL distilled water in a 250 mL round bottom (RB) flask. 
Then p-toluenesulfonyl chloride (a; 15.0 mmol) was added 
to the reaction mixture gradually over 15-20 minutes. The 
pH was maintained at 9.0 by basic aqueous solution of 
Na2CO3 (5%) at room temperature. The reaction mixture 
was stirred for 3-4 hours and monitored using TLC. At 
the completion of the reaction, concentrated HCl (11 M, 
2 mL) was slowly added to adjust the pH to 6.0 and 
allowed to stand for 10-15 minutes. The precipitate was 
filtered and washed with cold distilled water to yield on 
drying the desired white-colored compound 1. White 
amorphous solid; yield: 89%; M.P.: 70-72 oC; molecular 
formula: C15H21NO4S; molecular weight: 311; IR (KBr, 
cm-1) υmax: 3067 (C-H stretching of aromatic ring), 1732 
(C=O stretching), 1531 (C=C aromatic stretching), 1335 
(-SO2- stretching), 1079 (C-O bond stretching); 1H-NMR 
(400 MHz, CDCl3, δ / ppm): 7.62 (d, J = 8.0 Hz, 2H, H-2’’ 
& H-6’’), 7.32 (d, J = 8.0 Hz, 2H, H-3’’ & H-5’’), 3.98 (q, 
J = 7.2 Hz, 2H, O-CH2), 3.71-3.68 (m, 2H, He-2’ & He-6’), 
2.73-2.62 (m, 1H, H-4’), 2.54-2.48 (m, 2H, Ha-2’ & Ha-6’), 
2.42 (s, 3H, CH3-4’’), 2.10-2.08 (m, 2H, He-3’ & He-5’), 
1.60-1.86 (m, 2H, Ha-3’ & Ha-5’), 1.15 (t, J = 7.2 Hz, 
CH3); EIMS (m/z): 311 [M]+, 266 [C13H16NO3S]+, 238 
[C12H16NO2S]+, 184 [C8H10NO2S]+, 170 [C7H8NO2S]+, 155 
[C7H7O2S]+, 91 [C7H7]+.
Preparation of 1-(4-tosyl)piperidin-4-
carbohydrazide (2)
Ethyl 1-(4-tosyl)piperidin-4-carboxylate (1; 
13.0 mmol) was dissolved in 20 mL methanol in a 250 mL 
RB flask. Hydrazine hydrate (80%, 10 mL) was added 
dropwise to the reaction mixture, which was then refluxed 
for 4-5 hours. Completion of the reaction was determined 
by TLC. At the end of the reaction, excess solvent was 
evaporated to yield a white crystalline product, compound 
2, which was washed with cold distilled water and dried. 
White crystalline solid; yield: 91%; M.P.: 128-130 oC; 
molecular formula: C13H19N3O3S; molecular weight: 
297; IR (KBr, cm-1) υmax: 3348 (N-H stretching), 3063 
(C-H stretching of aromatic ring), 1682 (C=O stretching), 
1534 (C=C aromatic stretching), 1339 (-SO2- stretching); 
1H-NMR (400 MHz, CDCl3, δ / ppm): 7.61 (d, J = 8.0 Hz, 
2H, H-2’’ & H-6’’), 7.33 (d, J = 8.0 Hz, 2H, H-3’’ & H-5’’), 
3.72-3.69 (m, 2H, He-2’ & He-6’), 2.73-2.62 (m, 1H, H-4’), 
2.53-2.49 (m, 2H, Ha-2’ & Ha-6’), 2.42 (s, 3H, CH3-4’’), 
2.12-2.10 (m, 2H, He-3’ & He-5’), 1.58-1.84 (m, 2H, Ha-3’ 
& Ha-5’); EIMS (m/z): 297 [M]+, 266 [C13H16NO3S]+, 238 
[C12H16NO2S]+, 184 [C8H10NO2S]+, 170 [C7H8NO2S]+, 155 
[C7H7O2S]+, 91 [C7H7]+.
Preparation of 5-(1-(4-tosyl)piperidin-4-yl)-1,3,4-
oxadiazol-2-thiol (3)
1-(4-Tosyl)piperidin-4-carbohydrazide (2 ; 
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11.0 mmol) was dissolved in methanol (30 mL) in a 
250-mL RB flask. Potassium hydroxide (11.0 mmol) 
and carbon disulfide (22.0 mmol) were added to the 
reaction mixture. The reaction mixture was refluxed for 
5-6 hours and monitored for completion with TLC. At 
the completion of reaction, chilled distilled water (50 
mL) was added to the reaction mixture, which was then 
acidified to pH 2-3 with dilute hydrochloric acid to yield 
a solid precipitate. An off-white precipitate of product 3 
was filtered, washed with cold distilled water and dried. 
White amorphous solid; yield: 87%; M.P.: 230-233 oC; 
molecular formula: C14H17N3O3S2; molecular weight: 339; 
IR (KBr, cm-1) υmax: 3067 (C-H stretching of aromatic 
ring), 2522 (S-H bond stretching), 1641 (C=N stretching 
of oxadiazole ring), 1541 (C=C aromatic stretching), 1345 
(-SO2- stretching), 1249 & 1079 (C-O-C bond stretching); 
1H-NMR (400 MHz, CDCl3, δ / ppm): 7.63 (d, J = 8.0 Hz, 
2H, H-2’’ & H-6’’), 7.32 (d, J = 8.0 Hz, 2H, H-3’’ & H-5’’), 
3.71-3.68 (m, 2H, He-2’ & He-6’), 2.74-2.63 (m, 1H, H-4’), 
2.54-2.48 (m, 2H, Ha-2’ & Ha-6’), 2.42 (s, 3H, CH3-4’’), 
2.10-2.08 (m, 2H, He-3’ & He-5’), 1.59-1.85 (m, 2H, Ha-3’ 
& Ha-5’); EIMS (m/z): 339 [M]+, 266 [C13H16NO3S]+, 238 
[C12H16NO2S]+, 184 [C8H10NO2S]+, 170 [C7H8NO2S]+, 155 
[C7H7O2S]+, 91 [C7H7]+.
General procedure for the synthesis of 
S-substituted derivatives of 3 (5a-h)
A calculated amount of 5-(1-(4-tosyl)piperidin-4-
yl)-1,3,4-oxadiazol-2-thiol (3; 8.0 mmol) was added to a 
50-mL RB flask. N,N-Dimethylformamide (DMF, 10 mL) 
was added to dissolve 3, followed by the addition of 
sodium hydride (8.0 mmol) to the reaction mixture at room 
temperature and stirring for 0.5 hour. The aralkyl halides 
4a-h were then added in an equimolar ratio to 3, and the 
reaction was further stirred for 3-4 hours. The progress 
of reaction was monitored with TLC until a single spot 
was obtained. Distilled water was added to the reaction 
mixture, and products 5a-h were recovered by filtration, 
which were then washed and dried.
4-(2-(Benzylthio)-1,3,4-oxadiazol-5-yl)-1-(4-tosyl)
piperidine (5a)
White crystalline solid; yield: 85%; M.P.: 128-
130 oC; molecular formula: C21H23N3O3S2; molecular 
weight: 429; IR (KBr, cm-1) υmax: 3047 (C-H stretching of 
aromatic ring), 1649 (C=N stretching of oxadiazole ring), 
1544 (C=C aromatic stretching), 1339 (-SO2- stretching), 
1248 & 1079 (C-O-C bond stretching); 1H-NMR (400 
MHz, CDCl3, δ / ppm): 7.62 (d, J = 8.0 Hz, 2H, H-2’’ & 
H-6’’), 7.31 (d, J = 7.6 Hz, 2H, H-3’’ & H-5’’), 7.38-7.26 
(m, 5H, H-2’’’ to H-6’’’), 4.40(s, 2H, CH2-7’’’), 3.66-
3.63 (m, 2H, He-2’ & He-6’), 2.84-2.79 (m, 1H, H-4’), 
2.60-2.53 (m, 2H, Ha-2’ & Ha-6’), 2.42 (s, 3H, CH3-4’’), 
2.10-2.05 (m, 2H, He-3’ & He-5’), 1.98-1.89 (m, 2H, Ha-
3’ & Ha-5’);EIMS (m/z): 429 [M]+, 266 [C13H16NO3S]+, 
2 3 8  [ C 1 2H 1 6N O 2S ] + ,  1 8 4  [ C 8H 1 0N O 2S ] + ,  1 7 0 
[C7H8NO2S]+, 155 [C7H7O2S]+, 91 [C7H7]+, 83 [C5H9N]+, 
51 [C4H3]+.
4-(2-(4-Fluorobenzylthio)-1,3,4-oxadiazol-5-yl)-1-(4-
tosyl)piperidine (5b)
White amorphous solid; yield: 83%; M.P.: 135-
137 oC; molecular formula: C21H22FN3O3S2; molecular 
weight: 447; IR (KBr, cm-1) υmax: 3055 (C-H stretching of 
aromatic ring), 1658 (C=N stretching of oxadiazole ring), 
1554 (C=C aromatic stretching), 1361 (-SO2- stretching), 
1256 & 1087 (C-O-C bond stretching), 1178 (C-F bond 
stretching); 1H-NMR (400 MHz, CDCl3, δ / ppm): 7.62 (d, 
J = 8.0 Hz, 2H, H-2’’ & H-6’’), 7.35 (dist. dd, J(b,a& b,19F) = 
8.8, 5.2 Hz, 2Hb, H-2’’’ & H-6’’’), 7.31 (d, J = 8.0 Hz, 2H, 
H-3’’ & H-5’’), 6.98 (br. t, J(a,b& a,19F) = 8.8 Hz, 2Ha, H-3’’’ 
& H-5’’’), 4.37 (s, 2H, CH2-7’’’), 3.67-3.64 (m, 2H, He-
2’ & He-6’), 2.85-2.78 (m, 1H, H-4’), 2.59-2.53 (m, 2H, 
Ha-2’ & Ha-6’), 2.42 (s, 3H, CH3-4’’), 2.10-2.06 (m, 2H, 
He-3’ & He-5’), 1.98-1.89 (m, 2H, Ha-3’ & Ha-5’); EIMS 
(m/z): 447 [M]+, 266 [C13H16NO3S]+, 238 [C12H16NO2S]+, 
184 [C8H10NO2S]+, 170 [C7H8NO2S]+, 155 [C7H7O2S]+ 
109 [C7H6F]+, 91 [C7H7]+, 90 [C7H6]+, 83 [C5H9N]+, 83 
[C5H4F]+, 64 [C5H4]+, 51 [C4H3]+.
4-(2-(2-Chlorobenzylthio)-1,3,4-oxadiazol-5-yl)-1-(4-
tosyl)piperidine (5c)
Fluffy white amorphous solid; yield: 78%; M.P.: 205-
207 oC; molecular formula: C21H22ClN3O3S2; molecular 
weight: 463; IR (KBr, cm-1) υmax: 3043 (C-H stretching of 
aromatic ring), 1641 (C=N stretching of oxadiazole ring), 
1545 (C=C aromatic stretching), 1357 (-SO2- stretching), 
1245 & 1082 (C-O-C bond stretching),713 (C-Cl bond 
stretching); 1H-NMR (400 MHz, CDCl3, δ / ppm): 7.62 
(d, J = 8.0 Hz, 2H, H-2’’ & H-6’’), 7.53 (d, J= 6.8 Hz, 1H, 
H-3’’’), 7.37 (dd, J= 7.6, 1.2 Hz, 1H, H-6’’’), 7.31 (d, J 
= 8.0 Hz, 2H, H-3’’ & H-5’’), 7.24-7.17 (m, 2H, H-4’’’ & 
H-5’’’), 4.52 (s, 2H, CH2-7’’’), 3.67-3.64 (m, 2H, He-2’ & 
He-6’), 2.84-2.77 (m, 1H, H-4’), 2.59-2.54 (m, 2H, Ha-2’ 
& Ha-6’), 2.42 (s, 3H, CH3-4’’), 2.10-2.06 (m, 2H, He-3’ & 
He-5’), 1.98-1.90 (m, 2H, Ha-3’ & Ha-5’);EIMS (m/z): 465 
[M+2]+,463 [M]+, 266 [C13H16NO3S]+, 238 [C12H16NO2S]+, 
184 [C8H10NO2S]+, 170 [C7H8NO2S]+, 155 [C7H7O2S]+, 
125 [C7H6Cl]+, 99 [C5H4Cl]+, 90 [C6H6]+, 91 [C7H7]+, 83 
[C5H9N]+, 64 [C5H4]+, 51 [C4H3]+.
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4-(2-(3-Chlorobenzylthio)-1,3,4-oxadiazol-5-yl)-1-(4-
tosyl)piperidine (5d)
Fluffy white amorphous solid; yield: 78%; M.P.: 
168-170 oC; molecular formula: C21H22ClN3O3S2; 
molecular weight: 463; IR (KBr, cm-1) υmax: 3061 (C-H 
stretching of aromatic ring), 1654 (C=N stretching 
of oxadiazole ring), 1558 (C=C aromatic stretching), 
1364 (-SO2- stretching), 1256 & 1089 (C-O-C bond 
stretching),701 (C-Cl bond stretching); 1H-NMR (400 
MHz, CDCl3, δ/ppm): 7.63 (d, J = 8.4 Hz, 2H, H-2’’ & 
H-6’’), 7.37 (s, 1H, H-2’’’), 7.31 (d, J = 8.4 Hz, 2H, H-3’’ 
& H-5’’), 7.28-7.22 (m, 3H, H-4’’’ to H-6’’’), 4.35 (s, 2H, 
CH2-7’’’), 3.67-3.64 (m, 2H, He-2’ & He-6’), 2.86-2.78 
(m, 1H, H-4’), 2.59-2.53 (m, 2H, Ha-2’ & Ha-6’), 2.42 
(s, 3H, CH3-4’’), 2.10-2.06 (m, 2H, He-3’ & He-5’), 1.98-
1.89 (m, 2H, Ha-3’ & Ha-5’);EIMS (m/z): 465 [M+2]+,463 
[M]+, 266 [C13H16NO3S]+, 238 [C12H16NO2S]+, 184 
[C8H10NO2S]+, 170 [C7H8NO2S]+, 155 [C7H7O2S]+, 125 
[C7H6Cl]+, 99 [C5H4Cl]+, 90 [C6H6]+, 91 [C7H7]+, 83 
[C5H9N]+, 64 [C5H4]+, 51 [C4H3]+.
4-(2-(4-Chlorobenzylthio)-1,3,4-oxadiazol-5-yl)-1-(4-
tosyl)piperidine (5e)
White amorphous solid; yield: 85%; M.P.: 210-
212 oC; molecular formula: C21H22ClN3O3S2; molecular 
weight: 463; IR (KBr, cm-1) υmax: 3049 (C-H stretching of 
aromatic ring), 1639 (C=N stretching of oxadiazole ring), 
1543 (C=C aromatic stretching), 1356 (-SO2- stretching), 
1243 & 1078 (C-O-C bond stretching), 699 (C-Cl bond 
stretching); 1H-NMR (400 MHz, CDCl3, δ / ppm): 7.62 (d, 
J = 8.4 Hz, 2H, H-2’’ & H-6’’), 7.27 (d, J = 8.4 Hz, 2H, 
H-3’’ & H-5’’), 7.33-7.24 (m, 4H,H-2’’’, H-3’’’, H-5’’’ & 
H-6’’’), 4.35 (s, 2H, CH2-7’’’), 3.67-3.64 (m, 2H, He-2’ & 
He-6’), 2.84-2.79 (m, 1H, H-4’), 2.59-2.53 (m, 2H, Ha-2’ 
& Ha-6’), 2.42 (s, 3H, CH3-4’’), 2.10-2.05 (m, 2H, He-3’ & 
He-5’), 1.98-1.88 (m, 2H, Ha-3’ & Ha-5’);EIMS (m/z): 465 
[M+2]+,463 [M]+, 266 [C13H16NO3S]+, 238 [C12H16NO2S]+, 
184 [C8H10NO2S]+, 170 [C7H8NO2S]+, 155 [C7H7O2S, 
125 [C7H6Cl]+, 99 [C5H4Cl]+, 90 [C6H6]+, 91 [C7H7]+, 83 
[C5H9N]+, 64 [C5H4]+, 51 [C4H3]+.
4-(2-(2-Bromobenzylthio)-1,3,4-oxadiazol-5-yl)-1-(4-
tosyl)piperidine (5f)
White granular amorphous solid; yield: 81%; 
M.P.: 155-157 oC; molecular formula: C21H22BrN3O3S2; 
molecular weight: 507; IR (KBr, cm-1) υmax: 3053 (C-H 
stretching of aromatic ring), 1647 (C=N stretching of 
oxadiazole ring), 1546 (C=C aromatic stretching), 1361 
(-SO2- stretching), 1255 & 1082 (C-O-C bond stretching), 
602 (C-Br bond stretching); 1H-NMR (400 MHz, CDCl3, δ 
/ ppm): 7.62 (d, J = 8.0 Hz, 2H, H-2’’ & H-6’’), 7.63-7.55 
(m, 2H, H-3’’’ & H-6’’’), 7.31 (d, J = 8.0 Hz, 2H, H-3’’ 
& H-5’’), 7.16-7.12 (m, 2H, H-4’’’ & H-5’’’), 4.53 (s, 2H, 
CH2-7’’’), 3.67-3.64 (m, 2H, He-2’ & He-6’), 2.85-2.79 
(m, 1H, H-4’), 2.59-2.54 (m, 2H, Ha-2’ & Ha-6’), 2.42 
(s, 3H, CH3-4’’), 2.10-2.07 (m, 2H, He-3’ & He-5’), 1.98-
1.92 (m, 2H, Ha-3’ & Ha-5’);EIMS (m/z): 509 [M+2]+, 
507 [M]+, 266 [C13H16NO3S]+, 238 [C12H16NO2S]+, 184 
[C8H10NO2S]+, 169 [C7H6Br]+, 170 [C7H8NO2S]+, 155 
[C7H7O2S]+, 143 [C5H4Br]+, 90 [C7H6]+,91 [C7H7]+, 83 
[C5H9N]+, 64 [C5H4]+, 51 [C4H3]+.
4-(2-(4-Bromobenzylthio)-1,3,4-oxadiazol-5-yl)-1-(4-
tosyl)piperidine (5g)
Fluffy white amorphous solid; yield: 79%; M.P.: 
163-165 oC; molecular formula: C21H22BrN3O3S2; 
molecular weight: 507; IR (KBr, cm-1) υmax: 3070 (C-H 
stretching of aromatic ring), 1662 (C=N stretching of 
oxadiazole ring), 1551 (C=C aromatic stretching), 1368 
(-SO2- stretching), 1261 & 1092 (C-O-C bond stretching), 
582 (C-Br bond stretching); 1H-NMR (400 MHz, CDCl3, 
δ / ppm): 7.62 (d, J = 8.4 Hz, 2H, H-2’’ & H-6’’), 7.42 (d, 
J = 8.4 Hz, 2H, H-3’’’ & H-5’’’), 7.31 (d, J = 8.4 Hz, 2H, 
H-3’’ & H-5’’), 7.26 (d, J = 8.4 Hz, 2H, H-2’’’ & H-6’’’), 
4.34 (s, 2H, CH2-7’’’), 3.67-3.64 (m, 2H, He-2’ & He-6’), 
2.84-2.78 (m, 1H, H-4’), 2.59-2.52 (m, 2H, Ha-2’ & Ha-
6’), 2.42 (s, 3H, CH3-4’’), 2.09-2.05 (m, 2H, He-3’ & He-
5’), 1.97-1.88 (m, 2H, Ha-3’ & Ha-5’);EIMS (m/z): 509 
[M+2]+, 507 [M]+, 266 [C13H16NO3S]+, 238 [C12H16NO2S]+, 
184 [C8H10NO2S]+, 169 [C7H6Br]+, 170 [C7H8NO2S]+, 155 
[C7H7O2S]+, 143 [C5H4Br]+, 90 [C7H6]+,91 [C7H7]+, 83 
[C5H9N]+, 64 [C5H4]+, 51 [C4H3]+.
4-(2-(2-Methylbenzylthio)-1,3,4-oxadiazol-5-yl)-1-(4-
tosyl)piperidine (5h)
White amorphous solid; yield: 83%; M.P.: 190-
192 oC; molecular formula: C22H25N3O3S2; molecular 
weight: 443; IR (KBr, cm-1) υmax: 3067 (C-H stretching of 
aromatic ring), 1655 (C=N stretching of oxadiazole ring), 
1554 (C=C aromatic stretching), 1365 (-SO2- stretching), 
1259 & 1093 (C-O-C bond stretching); 1H-NMR (400 
MHz, CDCl3, δ / ppm): 7.63 (d, J = 8.0 Hz, 2H, H-2’’ & 
H-6’’), 7.32-7.30 (m, 3H, H-3’’, H-5’’ & H-3’’’), 7.18-
7.10 (m, 3H,H-4’’’to H-6’’’), 4.43 (s, 2H, CH2-7’’’), 
3.67-3.64 (m, 2H, He-2’ & He-6’), 2.85-2.79 (m, 1H, 
H-4’), 2.60-2.55 (m, 2H, Ha-2’ & Ha-6’), 2.42 (s, 3H, 
CH3-4’’), 2.39 (s, 3H, CH3-2’’’), 2.11-2.07 (m, 2H, He-3’ 
& He-5’), 1.99-1.93 (m, 2H, Ha-3’ & Ha-5’);EIMS (m/z): 
443 [M]+, 266 [C13H16NO3S]+, 238 [C12H16NO2S]+, 184 
[C8H10NO2S]+, 170 [C7H8NO2S]+, 155 [C7H7O2S]+, 106 
[C8H10]+, 91 [C7H7]+, 90 [C7H6]+, 83 [C5H9N]+, 65 [C5H4]+, 
51 [C4H3]+.
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Biological activity assays
Lipoxygenase inhibition assay
Lipoxygenase activity was assayed according to 
a previously reported method (Baylac, Racine, 2003; 
Nafeesa et al., 2015). The change in absorbance was 
determined at 234 nm for all the test compounds.
α-Glucosidase inhibition assay
α-Glucosidase inhibitory activity was performed 
according to a previously reported method (Abbasi et al., 
2014; Chapdelaine et al., 1978). The change in absorbance 
was determined at 400 nm for all the test compounds.
Antibacterial activity assay
The antibacterial activity was performed under 
aseptic conditions in sterile 96-well microplates. The 
principle of the method is that as microbial cell population 
increases during log phase growth, there is an increase 
in the absorbance of the broth medium (Kaspady et al., 
2009; Nafeesa et al., 2015). Ciprofloxacin was used as 
reference standard.
Statistical analysis
Minimum inhibitory concentration (MIC) for 
antibacterial activity and IC50 (concentration causing 
50% inhibition) for enzyme inhibition was determined 
with suitable dilutions for each sample, and results were 
calculated using EZ-Fit software (Perrella Scientific Inc., 
Amherst, NH, USA). The results are presented as mean ± 
SEM for triplicate determinations after statistical analysis 
performed with MS Excel 2010.
RESULTS AND DISCUSSION
The goal of our study was to produce S-substituted 
derivatives of oxadiazole compounds having p-toluene 
sulfonyl and piperidine moieties and also to screen them 
for enzyme inhibitory activity. A series of derivatives, 
5a-h, were synthesized according to the protocol given in 
Figure 1. The different aralkyl groups are given in Table I.
Chemistry
Compound 5a was synthesized as a white crystalline 
compound. The molecular formula C21H23N3O3S2 was 
established with molecular ion peak m/z 429 in EIMS 
and by proton counting using 1H-NMR spectra. The IR 
spectrum gave absorption bands at 3047, 1649, 1544, 
1339, 1248 and 1079 cm-1, which were assigned to C-H 
(stretching of aromatic ring), C=N (stretching of oxadiazole 
ring), C=C (aromatic stretching), -SO2 (stretching), and 
C-O-C (stretching of oxadiazole ring), respectively. In 
EIMS spectra, the peak at m/z 266 showed cleavage 
FIGURE 1 - Synthesis of S-substituted derivatives of 5-(1-(4-Tosyl)piperidin-4-yl)-1,3,4-oxadiazol-2-thiol (5a-h).
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of the benzyl sulfide group along with partial cleavage 
of the oxadiazole ring in 5a, while the peak at m/z 155 
showed the presence of the p-toluenesulfonyl group and 
the peak at m/z 83 the presence of a piperidine moiety. The 
other prominent fragments are given in Figure 2. In the 
aromatic region of 1H-NMR, signals appeared at δ 7.62 (d, 
J = 8.0 Hz, 2H, H-2’’ & H-6’’) and 7.31 (d, J = 7.6 Hz, 2H, 
H-3’’ & H-5’’), which were assigned to the toluenesulfony 
moiety; the signals appearing at δ 7.38-7.26 (m, 5H, 
H-2’’’ to H-6’’’) were assigned to the mono-substituted 
benzene ring of the benzyl moiety. The signals resonating 
at δ 3.66-3.63 (m, 2H, He-2’ & He-6’), 2.84-2.79 (m, 1H, 
H-4’), 2.60-2.53 (m, 2H, Ha-2’ & Ha-6’), 2.10-2.05 (m, 2H, 
He-3’ & He-5’) and1.98-1.89 (m, 2H, Ha-3’ & Ha-5’) were 
assigned to the piperidine moiety; and the signal at 4.40 
(s, 2H, CH2-7’’’) was assigned to the methylene group of 
the benzyl moiety. On the basis of the above findings, the 
structure of 5a was determined to be 4-(2-(benzylthio)-
1,3,4-oxadiazol-5-yl)-1-(4-tosyl)piperidine. In a similar 
way, the structures of other synthesized compounds were 
characterized by using 1H-NMR, IR and EIMS data.
Enzyme inhibitory activity (in vitro) 
The screening of synthesized compounds against 
the enzymes lipoxygenase and α-glucosidase revealed that 
most of the compounds were moderate to weakly moderate 
inhibitors of these enzymes. The experimental results are 
given in Table II below.
Screening of these synthesized compounds proved 
5b to be the most active inhibitor against lipoxygenase. 
Other compounds showed no activity, except 5d against 
this enzyme. Only the S-substituted benzyl compound 
containing fluorine at the para position showed better 
activity against this enzyme. The better activity of 5b was 
attributed to the presence of a fluorine at position ‘4’ in th 
ebenzyl moiety. The compounds 5d and 5f remained inactive 
against α-glucosidase. 5b showed the highest inhibitory 
activity with an IC50 of 181.92 ± 0.17 µM compared to 
38.25 ± 0.12 µM of acarbose, the reference standard. The 
high inhibitory activity of this compound could be attributed 
to the S-substituted benzyl moiety containing a highly 
electronegative group at the para position, which showed 
the best catalysis-blocking capability. The other compounds 
showed moderately weak inhibition, but all 4-substituted 
halogenated benzyl group-containing compounds had 
relatively better activity in a sequential order. The IC50 
values of 4-substituted halogenated benzyl group-
containing compounds indicated that the presence of small 
and more electronegative atoms leads to better inhibition of 
the enzyme. The inhibition order of molecules containing 
4-substituted halogenated benzyl group was fluorinated > 
chlorinated > brominated. The overall descending order 
of inhibitory activity of the synthesized molecules was as 
follows, 5b, 5e, 5c, 5a, 5g and 5h.
Antibacterial activity (in vitro)
The in vitro MIC and percentage inhibition results for 
antibacterial activity of the synthesized compounds against 
Gram-positive and Gram-negative bacteria are given in 
Tables III and IV, using ciprofloxacin as reference standard.
All the synthesized compounds displayed strong 
to moderate antibacterial activity against all the bacterial 
strains studied except for Staphylococcus aureus against 
which only 5h was moderately active. Compounds 5a and 
TABLE I - Different aralkyl groups
Comp. R Comp. R
5a
 
5e
 
5b
 
5f
 
5c
 
5g
 
5d
 
5h
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5g showed strong to moderate activity and 5b showed 
moderate activity against all strains except Staphylococcus 
aureus. 5h exhibited moderate activity against all except 
Pseudomonas aeruginosa. The compounds 5d and 5e 
were active against only three strains, Salmonella typhi, 
Escherichia coli and Bacillus subtilis. 5f was active only 
TABLE II - Enzyme inhibitory activity against lipoxygenase and α-glucosidase enzymes
Compound
Lipoxygenase (LOX) α-Glucosidase
Inhibition (%) 
at 0.5 mM
IC50 
µM
Inhibition (%) 
at 0.5 mM
IC50 
µM
5a 47.81 ± 0.06 - 65.22 ± 0.31 197.98 ± 0.11
5b 99.12 ± 0.41 78.38 ± 0.12 81.11 ± 0.24 181.92 ± 0.17
5c 11.71 ± 0.14 - 78.14 ± 0.31 195.53 ± 0.19
5d 56.95 ± 0.33 229.72 ± 0.16 11.33 ± 0.25 -
5e 12.25 ± 0.89 - 83.56 ± 0.16 185.58 ± 0.18
5f 47.43 ± 0.56 - 9.27 ± 0.12 -
5g 11.62 ± 0.41 - 61.55 ± 0.13 313.79 ± 0.07
5h 14.37 ± 0.29 - 84.46 ± 0.16 321.43 ± 0.14
Control 93.79 ± 1.27a 22.41 ± 1.3a 92.23 ± 0.14b 38.25 ± 0.12b
Note: a = Baicalein, b = Acarbose. IC50 values (concentration at which there is 50% enzyme inhibition) of compounds were 
calculated using EZ-Fit Enzyme Kinetics software (Perrella Scientific Inc.)
FIGURE 2 -Proposed mass fragmentation pattern of 4-(2-(benzylthio)-1,3,4-oxadiazol-5-yl)-1-(4-tosyl)piperidine (5a).
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against two strains, Salmonella typhi and Bacillus subtilis, 
while 5c showed no activity at all. Against Salmonella 
typhi, the three compounds 5e, 5f and 5g were the most 
efficient with MIC values of 9.15 ± 0.24, 8.24 ± 0.90 and 
9.69 ± 0.16 µM, respectively, relative to 7.45 ± 0.58, MIC 
of reference. Against Escherichia coli, the two compounds 
5d and 5e showed the lowest MIC values, i.e., 9.78 ± 0.66 
and 10.09 ± 0.05 µM, respectively, relative to that of the 
reference, 7.16 ± 0.58 µM. 5a, 5f and 5g inhibited Bacillus 
subtilis with MIC values of 9.65 ± 0.24, 9.10 ± 0.41 and 
9.27 ± 0.17 µM, respectively, compared to 7.14 ± 0.18 µM 
for the reference drug. The overview of the most active 
compounds revealed that the nature and position of 
halogen-substitution in the molecule greatly affected the 
biological behavior of the molecules.
CONCLUSION
The structures of the synthesized compounds are 
supported by spectroscopic data. From enzyme inhibition 
and antibacterial data, it was evident that different 
S-substituted derivatives of 5-(1-(4-tosyl)piperidin-4-yl)-
1,3,4-oxadiazol-2-thiol are valuable enzyme inhibitors and 
potential antibacterial agents. It is interesting and worth 
knowing that α-glucosidase is inhibited by all 4-halogenated 
benzyl S-substituted compounds while lipoxygenase is 
inhibited by only 4-fluoro benzyl S-substituted compounds. 
This information could be used for selective inhibition of 
alpha-glucosidase and lipoxygenase and may be of use 
in drug discovery programs. The antibacterial activity 
suggested that compounds 5a, 5f and 5g against Bacillus 
subtilis, 5d against Escherichia coli and 5e, 5f and 5g 
against Salmonella typhi could be considered for further in 
vivo evaluation by the pharmaceutic industry.
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